Source comparison
Tesamorelin vs CJC-1295/Ipamorelin: Head-to-Head Comparison
Before examining individual mechanisms in detail, the following comparison table summarizes the key variables researchers use when evaluating tesamorelin vs CJC-1295 Ipamorelin for a given study protocol. Both compounds have demonstrated GH secretagogue activi
This comparison does not assign a generated winner or score.
- Before examining individual mechanisms in detail, the following comparison table summarizes the key variables researchers use when evaluating tesamorelin vs CJC-1295 Ipamorelin for a given study protocol. Both compounds have demonstrated GH secretagogue activity in published research, but their clinical evidence depth, receptor mechanisms, dosing schedules, and validated endpoints differ substantially.
- Mechanism
- GHRH analog (single pathway)
- GHRH + GHRP (dual pathway synergy)
- FDA status
- FDA-approved (Egrifta, 2010)
- Not approved
- Clinical validation
- Phase III, 806 participants
- Components studied separately
- Key validated result
- 15.4% visceral fat reduction
- GH elevation documented in Phase I/II
- Dosing
- 2mg once daily
- 100/100mcg 2-3x daily
- Injection frequency
- 1x daily
- 2-3x daily
- GH elevation pattern
- Physiological pulsatile
- Amplified pulsatile (synergistic)
- Best for
- Visceral fat, validated dosing data
- Broad GH benefits, body composition
- PSPeptides price
- From $59.99
- $65.99 (pre-blended)